Pharmacogenomics and drug responseMÜLLER, M.International journal of clinical pharmacology and therapeutics. 2003, Vol 41, Num 6, pp 231-240, issn 0946-1965, 10 p.Article

Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failurePODER, P; EHA, J; SUNDBERG, S et al.International journal of clinical pharmacology and therapeutics. 2003, Vol 41, Num 8, pp 365-373, issn 0946-1965, 9 p.Article

Pharmacokinetics and pharmacodynamics of cisplatin after intra-operative Hyperthermic intraperitoneal chemoperfusion (HIPEC)ZEAMARI, S; FLOOT, B; VAN DER VANGE, N et al.Anticancer research. 2003, Vol 23, Num 2B, pp 1643-1648, issn 0250-7005, 6 p.Article

Comparative in vivo evaluation of propranolol hydrochloride after oral and transdermal administration in rabbitsRAMA RAO, P; NARENDER REDDY, M; RAMAKRISHNA, Sistla et al.European journal of pharmaceutics and biopharmaceutics. 2003, Vol 56, Num 1, pp 81-85, issn 0939-6411, 5 p.Article

Pharmacokinetic and pharmacodynamic analysis of platinum after combined treatment of cisplatin and procainamide hydrochloride in mice bearing P388 leukemiaVANNOZZI, Maria O; OTTONE, Massimo; MARIGGIO, Maria A et al.Anticancer research. 2003, Vol 23, Num 2B, pp 1509-1516, issn 0250-7005, 8 p.Article

Faropenem MedoxomilGETTIG, Jacob P; CRANK, Christopher W; PHILBRICK, Alexander H et al.The Annals of pharmacotherapy. 2008, Vol 42, Num 1, pp 80-90, issn 1060-0280, 11 p.Article

Contribution of modelling chemotherapy-induced hematological toxicity for clinical practiceTESTART-PAILLET, Diane; GIRARD, Pascal; YOU, Benoit et al.Critical reviews in oncology/hematology. 2007, Vol 63, Num 1, pp 1-11, issn 1040-8428, 11 p.Article

Tissue concentrations : do we ever learn?MOUTON, Johan W; THEURETZBACHER, Ursula; CRAIG, William A et al.Journal of antimicrobial chemotherapy (Print). 2008, Vol 61, Num 2, pp 235-237, issn 0305-7453, 3 p.Article

Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjectsWOJCICKI, Jerzy; JAROSZYNSKA, Maria; DROZDZIK, Marek et al.Biopharmaceutics & drug disposition. 2003, Vol 24, Num 5, pp 211-218, issn 0142-2782, 8 p.Article

The hollow fibre model -facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfareSUGGITT, Marie; COOPER, Patricia A; SHNYDER, Steven D et al.International journal of oncology. 2006, Vol 29, Num 6, pp 1493-1499, issn 1019-6439, 7 p.Article

Pharmacokinetics and tissue penetration of pefloxacin plus metronidazole after administration as surgical prophylaxis in colorectal surgeryGASCON, A. R; GUTIERREZ-ARAGON, G; HERNANDEZ, R. M et al.International journal of clinical pharmacology and therapeutics. 2003, Vol 41, Num 6, pp 267-274, issn 0946-1965, 8 p.Article

Understanding the time course of pharmacological effect: a PKPD approachWRIGHT, Daniel F. B; WINTER, Helen R; DUFFULL, Stephen B et al.British journal of clinical pharmacology. 2011, Vol 71, Num 6, pp 815-823, issn 0306-5251, 9 p.Article

Tissue distribution and elimination of N-methyl-N-2,4,6-tetranitroaniline (tetryl) in ratsMYERS, Steven R; SPINNATO, Joseph A.Archives of toxicology. 2007, Vol 81, Num 12, pp 841-848, issn 0340-5761, 8 p.Article

Amino acid pharmacokinetics and safety assessmentBIER, Dennis M.The Journal of nutrition. 2003, Vol 133, Num 6, pp 2034-2039, issn 0022-3166, 6 p., SUP1Conference Paper

Pharmacokinetic-pharmacodynamic modelling : History and perspectivesCSAJKA, Chantal; VEROTTA, Davide.Journal of pharmacokinetics and pharmacodynamics (Print). 2006, Vol 33, Num 3, pp 227-279, issn 1567-567X, 53 p.Article

Modelling the genesis and treatment of cancer: The potential role of physiologically based pharmacodynamicsSTEIMER, Jean-Louis; DAHL, Svein G; FRIBERG, Lena E et al.European journal of cancer (1990). 2010, Vol 46, Num 1, pp 21-32, issn 0959-8049, 12 p.Article

Entry-into-humans study with a new direct renin inhibitorNICOLAS, Laurent B; GUTIERREZ, Marcelo M; BINKERT, Christoph et al.European journal of clinical pharmacology. 2012, Vol 68, Num 9, pp 1257-1266, issn 0031-6970, 10 p.Article

Target-mediated drug disposition and dynamicsMAGER, Donald E.Biochemical pharmacology. 2006, Vol 72, Num 1, pp 1-10, issn 0006-2952, 10 p.Article

Population clinical pharmacology of children : modelling covariate effectsANDERSON, Brian J; ALLEGAERT, Karel; HOLFORD, Nicholas H. G et al.European journal of pediatrics. 2006, Vol 165, Num 12, pp 819-829, issn 0340-6199, 11 p.Article

The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trialsMARCHETTI, S; SCHELLENS, J. H. M.British journal of cancer. 2007, Vol 97, Num 5, pp 577-581, issn 0007-0920, 5 p.Article

Edoxaban administration following enoxaparin: A pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjectsZAHIR, Hamim; MATSUSHIMA, Nobuko; HALIM, Abdel-Baset et al.Thrombosis and haemostasis. 2012, Vol 108, Num 1, pp 166-175, issn 0340-6245, 10 p.Article

In vitro and in vivo pharmacokinetic/ pharmacodynamic activity of clofoctolSCAGLIONE, Francesco; DUGNANI, Silvana; LUCINI, Valeria et al.Journal of chemotherapy (Testo stampato). 2012, Vol 24, Num 4, pp 201-206, issn 1120-009X, 6 p.Article

Interpreting population pharmacokinetic-pharmacodynamic analyses -a clinical viewpointDUFFULL, Stephen B; WRIGHT, Daniel F. B; WINTER, Helen R et al.British journal of clinical pharmacology. 2011, Vol 71, Num 6, pp 807-814, issn 0306-5251, 8 p.Article

Pharmacogenomics of antipsychotics efficacy for schizophreniaCACABELOS, Ramón; HASHIMOTO, Ryota; TAKEDA, Masatoshi et al.Psychiatry and clinical neurosciences (Carlton. Print). 2011, Vol 65, Num 1, pp 3-19, issn 1323-1316, 17 p.Article

Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclinesAGWUH, Kenneth N; MACGOWAN, Alasdair.Journal of antimicrobial chemotherapy (Print). 2006, Vol 58, Num 2, pp 256-265, issn 0305-7453, 10 p.Article